Back to top
more

Bausch + Lomb (BLCO)

(Delayed Data from NYSE)

$14.59 USD

14.59
147,311

+0.08 (0.55%)

Updated May 21, 2024 04:00 PM ET

After-Market: $14.58 -0.01 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (94 out of 248)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Earnings Preview: Alignment Healthcare (ALHC) Q1 Earnings Expected to Decline

by Zacks Equity Research

Alignment Healthcare (ALHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Bausch + Lomb (BLCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BLCO vs. AVTR: Which Stock Is the Better Value Option?

by Zacks Equity Research

BLCO vs. AVTR: Which Stock Is the Better Value Option?

All You Need to Know About Bausch + Lomb (BLCO) Rating Upgrade to Buy

by Zacks Equity Research

Bausch + Lomb (BLCO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

BLCO or AVTR: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

BLCO vs. AVTR: Which Stock Is the Better Value Option?

BLCO or AVTR: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

BLCO vs. AVTR: Which Stock Is the Better Value Option?

Surging Earnings Estimates Signal Upside for Bausch + Lomb (BLCO) Stock

by Zacks Equity Research

Bausch + Lomb (BLCO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Compared to Estimates, Bausch + Lomb (BLCO) Q4 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Bausch + Lomb (BLCO) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Seeking Clues to Bausch + Lomb (BLCO) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for Bausch + Lomb (BLCO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.

Will Bausch + Lomb (BLCO) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Bausch + Lomb (BLCO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Bausch + Lomb (BLCO) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Bausch + Lomb (BLCO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bausch + Lomb (BLCO) Reports Q3 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

The headline numbers for Bausch + Lomb (BLCO) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Analysts Estimate Organon (OGN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bausch + Lomb (BLCO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Bausch + Lomb (BLCO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aldeyra (ALDX) Plummets on Dry Eye Disease Drug's Setback

by Zacks Equity Research

Aldeyra's (ALDX) new drug application for dry eye disease unlikely to be approved by the FDA due to its lack of efficacy.

Novartis (NVS) Spins off Sandoz, Reiterates Annual Outlook

by Zacks Equity Research

Novartis (NVS) separates Sandoz into an independent company. The company reaffirms the previously provided guidance.

Novartis (NVS) Announces Positive Data on Kidney Disease Drug

by Zacks Equity Research

Novartis' (NVS) phase III study on pipeline candidate iptacopan in patients with IgAN shows superiority versus placebo in proteinuria reduction.

Is the Options Market Predicting a Spike in Bausch + Lomb (BLCO) Stock?

by Zacks Equity Research

Investors need to pay close attention to Bausch + Lomb (BLCO) stock based on the movements in the options market lately.

Novartis' (NVS) Shareholders Approve Sandoz Separation

by Zacks Equity Research

Novartis' (NVS) shareholders vote in favor of the 100% spin-off of Sandoz into a new publicly traded standalone company.

DocGo Inc. (DCGO) Moves 6.8% Higher: Will This Strength Last?

by Zacks Equity Research

DocGo Inc. (DCGO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

InnovAge Holding Corp. (INNV) Soars 15.4%: Is Further Upside Left in the Stock?

by Zacks Equity Research

InnovAge Holding Corp. (INNV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Novartis (NVS) Plans to Spin-Off Sandoz in Early October

by Zacks Equity Research

Novartis (NVS) progresses with the proposed spin-off of its Sandoz arm (scheduled for early October) and invites shareholders for a meeting on the same.

Novartis (NVS) Key Drugs and Pipeline Progress Fuel Growth

by Zacks Equity Research

Novartis (NVS) put up a strong performance year to date based on the solid performance of key drugs and encouraging pipeline progress.

Bausch + Lomb (BLCO) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Bausch + Lomb (BLCO) delivered earnings and revenue surprises of 12.50% and 7.74%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Icon PLC (ICLR) Surpasses Q2 Earnings Estimates

by Zacks Equity Research

Icon PLC (ICLR) delivered earnings and revenue surprises of 0.97% and 0.03%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?